AMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women’s health, and anemia management in the United States.
Fair value with moderate growth potential.
Share Price & News
How has AMAG Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AMAG's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: AMAG underperformed the US Pharmaceuticals industry which returned 6.9% over the past year.
Return vs Market: AMAG underperformed the US Market which returned 8.9% over the past year.
Price Volatility Vs. Market
How volatile is AMAG Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StAre Investors Undervaluing AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) By 44%?
1 month ago | Simply Wall StDoes AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Have A Volatile Share Price?
2 months ago | Simply Wall StEarnings Release: Here's Why Analysts Cut Their AMAG Pharmaceuticals, Inc. Price Target To US$9.78
Is AMAG Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AMAG ($8.63) is trading below our estimate of fair value ($17.2)
Significantly Below Fair Value: AMAG is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AMAG is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: AMAG is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AMAG's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AMAG is good value based on its PB Ratio (1.1x) compared to the US Pharmaceuticals industry average (3.4x).
How is AMAG Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMAG is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: AMAG is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AMAG's is expected to become profitable in the next 3 years.
Revenue vs Market: AMAG's revenue is expected to decline over the next 3 years (-5.7% per year).
High Growth Revenue: AMAG's revenue is forecast to decline over the next 3 years (-5.7% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AMAG's Return on Equity is forecast to be low in 3 years time (0.2%).
How has AMAG Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AMAG is currently unprofitable.
Growing Profit Margin: AMAG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AMAG is unprofitable, and losses have increased over the past 5 years at a rate of -65.7% per year.
Accelerating Growth: Unable to compare AMAG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AMAG is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.5%).
Return on Equity
High ROE: AMAG has a negative Return on Equity (-139.86%), as it is currently unprofitable.
How is AMAG Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: AMAG's short term assets ($290.6M) exceed its short term liabilities ($188.2M).
Long Term Liabilities: AMAG's short term assets ($290.6M) do not cover its long term liabilities ($301.6M).
Debt to Equity History and Analysis
Debt Level: AMAG's debt to equity ratio (106.6%) is considered high.
Reducing Debt: AMAG's debt to equity ratio has increased from 72.8% to 106.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AMAG has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AMAG has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is AMAG Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AMAG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AMAG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AMAG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AMAG's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AMAG's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bill Heiden (59yo)
Dr. William K. Heiden, also known as Bill, was the Chief Executive Officer of AMAG Pharmaceuticals, Inc. since May 14, 2012 until April 28, 2020 and served as its President until April 28, 2020. Dr. Heiden ...
CEO Compensation Analysis
Compensation vs Market: Bill's total compensation ($USD4.87M) is above average for companies of similar size in the US market ($USD1.33M).
Compensation vs Earnings: Bill's compensation has been consistent with company performance over the past year.
|CEO, President & Director||8.08yrs||US$4.87m||0.57% $1.7m|
|Executive VP||4.17yrs||US$1.44m||0.080% $235.8k|
|Executive VP of Legal Affairs & Quality||4.83yrs||US$1.41m||0.081% $240.8k|
|Executive VP & Chief Commercial Officer||3.75yrs||US$1.38m||0.043% $126.9k|
|President||0.17yr||no data||no data|
|Vice President of Investor Relations & Corporate Communications||no data||no data||no data|
|Chief Compliance Officer||2.75yrs||no data||no data|
|Vice President of Marketing||6.92yrs||no data||no data|
|Senior VP & Chief Human Resources Officer||no data||no data||0.022% $64.2k|
|Senior Vice President of Clinical Development||2.75yrs||no data||no data|
Experienced Management: AMAG's management team is considered experienced (4 years average tenure).
|CEO, President & Director||8.08yrs||US$4.87m||0.57% $1.7m|
|President||0.17yr||no data||no data|
|Independent Director||6.17yrs||US$242.17k||0.049% $144.2k|
|Independent Director||13.5yrs||US$257.49k||0.074% $220.2k|
|Independent Director||11.42yrs||US$232.49k||0.074% $220.2k|
|Independent Director||6.75yrs||US$237.49k||0.053% $157.4k|
|Independent Chairman||6.17yrs||US$279.99k||0.067% $199.3k|
|Independent Director||5.75yrs||US$249.99k||0.055% $163.8k|
|Independent Director||1.17yrs||US$261.83k||no data|
|Independent Director||1.17yrs||US$269.64k||no data|
Experienced Board: AMAG's board of directors are considered experienced (6.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
AMAG Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: AMAG Pharmaceuticals, Inc.
- Ticker: AMAG
- Exchange: NasdaqGS
- Founded: 1981
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$295.774m
- Shares outstanding: 34.27m
- Website: https://www.amagpharma.com
Number of Employees
- AMAG Pharmaceuticals, Inc.
- 1100 Winter Street
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AMAG||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jun 1986|
|AMU||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 1986|
AMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women’s health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/05 03:51|
|End of Day Share Price||2020/06/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.